Pfizer, Pharmacia Protest Inclusion Of Drug Innovator Data In "Paper NDAs"
Executive Summary
Pfizer and Pharmacia are requesting that FDA revise a draft guidance so that "paper NDAs" approved under section 505(b)(2) of the Waxman/Hatch patent law would not be allowed to rely on non-published studies conducted by the product innovator.
You may also be interested in...
BIO Petition Opposes Generic Insulin, HGH; Asks FDA To Open Public Debate
The Biotechnology Industry Organization is asking FDA to initiate a public comment process on generic biologics before it moves forward in creating approval pathways for generic therapeutic proteins
BIO Petition Opposes Generic Insulin, HGH; Asks FDA To Open Public Debate
The Biotechnology Industry Organization is asking FDA to initiate a public comment process on generic biologics before it moves forward in creating approval pathways for generic therapeutic proteins
Pfizer Norvasc Patent Term Extension Coverage: The Product Or The Use?
A patent term extension for Pfizer's Norvasc applies only to the besylate salt of amlodipine, Dr. Reddy's said in its motion to dismiss Pfizer's patent infringement suit